A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 286 participants.

Also called NCT05342623

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 286 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05342623
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05342623. Randomized; double masking; primary purpose treatment. Start 2022-05-17 (actual); primary completion 2024-02-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
Condition
Chronic Kidney Diseases
Condition
Pruritus
Intervention (Drug)
Difelikefalin 1 mg Oral Tablet
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
Cara Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05342623
Content hash
a2b9b5d3bbb9e561705cd6215b5569922261daaf2673b73ea15aa7ea1a0ab51d